Qianwen Liu1,2,3,4, Xiayu Fu1,2,3,4, Xiaodong Su1,2,3,4, Xin Wang1,2,3,4, Yijun Zhang2,3,4,5, Hong Yang1,2,3,4, Yi Hu1,2,3,4, Jing Wen1,2,3,4, Jianhua Fu1,2,3,4. 1. Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. 2. State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. 3. Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. 4. Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. 5. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Abstract
BACKGROUND: The prognostic significance of serum lactate dehydrogenase (LDH) level in thymic carcinoma (TC) remains unclear. Therefore, we evaluated the role of pretreatment serum LDH level in the prognosis for TC in this study. METHODS: Sixty consecutive surgical patients were analyzed in this study with pathologic confirmed TC in Sun Yat-sen University Cancer Center from June 1996 to June 2014. RESULTS: The cut-off value of LDH was 210.50 IU/L. In both univariate analysis and multivariable analysis, only pretreatment serum LDH level (P=0.027) and pathological Masaoka stage (P=0.041) were associated with overall survival (OS). In univariate analysis, pretreatment serum LDH level, tumor size, postoperative radiotherapy (PORT) and pathological Masaoka stage were associated with disease-free survival (DFS) (all P<0.050). Multivariable analysis showed that LDH level (P=0.001), PORT (P=0.001) and pathological Masaoka stage (P=0.038) were independently prognostic factors of DFS. This study also revealed that male patients and larger tumor size had a significantly higher rate of elevated pretreatment serum LDH level than in the other groups. CONCLUSIONS: In conclusion, pretreatment serum LDH level was an independent prognosis factor of OS and DFS for patients with TC.
BACKGROUND: The prognostic significance of serum lactate dehydrogenase (LDH) level in thymic carcinoma (TC) remains unclear. Therefore, we evaluated the role of pretreatment serum LDH level in the prognosis for TC in this study. METHODS: Sixty consecutive surgical patients were analyzed in this study with pathologic confirmed TC in Sun Yat-sen University Cancer Center from June 1996 to June 2014. RESULTS: The cut-off value of LDH was 210.50 IU/L. In both univariate analysis and multivariable analysis, only pretreatment serum LDH level (P=0.027) and pathological Masaoka stage (P=0.041) were associated with overall survival (OS). In univariate analysis, pretreatment serum LDH level, tumor size, postoperative radiotherapy (PORT) and pathological Masaoka stage were associated with disease-free survival (DFS) (all P<0.050). Multivariable analysis showed that LDH level (P=0.001), PORT (P=0.001) and pathological Masaoka stage (P=0.038) were independently prognostic factors of DFS. This study also revealed that male patients and larger tumor size had a significantly higher rate of elevated pretreatment serum LDH level than in the other groups. CONCLUSIONS: In conclusion, pretreatment serum LDH level was an independent prognosis factor of OS and DFS for patients with TC.
Authors: D Blumberg; M E Burt; M S Bains; R J Downey; N Martini; V Rusch; R J Ginsberg Journal: J Thorac Cardiovasc Surg Date: 1998-02 Impact factor: 5.209
Authors: James Huang; Nabil P Rizk; William D Travis; Gregory J Riely; Bernard J Park; Manjit S Bains; Joseph Dycoco; Raja M Flores; Robert J Downey; Valerie W Rusch Journal: J Thorac Cardiovasc Surg Date: 2009-07 Impact factor: 5.209
Authors: Alexander Marx; Philipp Ströbel; Sunil S Badve; Lara Chalabreysse; John K C Chan; Gang Chen; Laurence de Leval; Frank Detterbeck; Nicolas Girard; Jim Huang; Michael O Kurrer; Libero Lauriola; Mirella Marino; Yoshihiro Matsuno; Thierry Jo Molina; Kiyoshi Mukai; Andrew G Nicholson; Daisuke Nonaka; Ralf Rieker; Juan Rosai; Enrico Ruffini; William D Travis Journal: J Thorac Oncol Date: 2014-05 Impact factor: 15.609
Authors: Saskia E Rademakers; Jasper Lok; Albert J van der Kogel; Johan Bussink; Johannes H A M Kaanders Journal: BMC Cancer Date: 2011-05-12 Impact factor: 4.430
Authors: Daniel Valdivia; Danjouma Cheufou; Benjamin Fels; Stephan Puhlvers; Khaled Mardanzai; Mohamed Zaatar; Gerhard Weinreich; Christian Taube; Dirk Theegarten; Martin Stuschke; Martin Schuler; Georgios Stamatis; Balazs Hegedus; Clemens Aigner Journal: Pathol Oncol Res Date: 2021-04-21 Impact factor: 3.201